Puerarin, for example, has antioxidative and anti-inflammatory activity [43] and can exhibit therapeutic effect on NAFLD by antioxidation, lowering cholesterol, and improving leptin signal transduction [44, 45], while berberine improves glucose metabolism by inhibition of hepatic gluconeogenesis [46] and reduces methylation of the microsomal triglyceride transfer protein promoter in fatty liver [42]. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.